BioSpace News Archive

Viracta Therapeutics, Inc. today announced that it has reacquired the exclusive rights to develop and commercialize its all-oral combination product candidate in the People’s Republic of China previously licensed to Shenzhen Salubris Pharmaceuticals Co., Ltd.

NGM Biopharmaceuticals, Inc. today disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well as with other ligands.

Medigen Vaccine Biologics Corporation today announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approximately 600,000 people are anticipated to receive the Medigen vaccine this week.

Mainstay Medical Holdings plc today announced its participation in the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, to be hosted virtually on August 21-25, 2021. i

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Jim Wang, Ph.D., has been appointed senior vice president, head of regulatory affairs

WuXi Biologics (Cayman) Inc. (“WuXi Biologics” or “the Company”, together with its subsidiaries “the Group”, stock code: 2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the six months, ending on June 30, 2021.

Today, Excelra, a global data science and data analytics company, unveiled an improved version of GOSTAR, its flagship chemistry insights engine.

Plasma therapy is one of the conservative techniques that is majorly used in dentistry, orthopedic, and dermatologic specialties.

Hepagene Therapeutics, Inc. today announced positive results from its Phase I study of HPG1860 conducted in the United States .

Today, the U.S. Food and Drug Administration approved the first COVID-19 vaccine. The vaccine has been known as the Pfizer-BioNTech COVID-19 Vaccine, and will now be marketed as Comirnaty